Infections · eLife · 2024
Acid-reducing pills and COVID-19: the summary’s risk figures belong to other nose, throat and chest infections
Times as likely as non-users; lines show ranges; grey rows are other infections
The paper says
The summary of this UK study says people on acid-reducing pills were 1.19 times as likely as non-users to be hospitalized for COVID-19 and 1.37 times as likely to die of it, each pinned to a narrow range: 1.11 to 1.27 and 1.29 to 1.46.
Its own data show
Those numbers and ranges match, digit for digit, the paper’s table figures for catching other airway infections: nose and throat (1,118 infections among pill users) and chest (1,486). Its results section gives the actual COVID-19 figures, based on 138 pill users hospitalized and 48 deaths: 1.33 times (1.09 to 1.61) and 1.46 (1.05 to 2.03).
A range spans the values the data can’t rule out; fewer deaths or illnesses widen it. The summary’s risks are smaller (1.19, not 1.33; 1.37, not 1.46) and far too certain: 48 deaths allow anything from 1.05 to 2.03. Most readers use the summary’s numbers; combined with other studies, its death figure would count about 28 times too heavily.